Annual report [Section 13 and 15(d), not S-K Item 405]

Cover

v3.25.2
Cover - USD ($)
 12 Months Ended
Apr. 30, 2025
Apr. 30, 2024
Aug. 04, 2025
Oct. 31, 2024
Cover [Abstract]        
Document Type 10-K      
Amendment Flag false      
Document Annual Report true      
Document Transition Report false      
Document Period End Date Apr. 30, 2025      
Document Fiscal Period Focus FY      
Document Fiscal Year Focus 2025      
Current Fiscal Year End Date --04-30      
Entity File Number 001-40699      
Entity Registrant Name PHARMACYTE BIOTECH, INC.      
Entity Central Index Key 0001157075      
Entity Tax Identification Number 62-1772151      
Entity Incorporation, State or Country Code NV      
Entity Address, Address Line One 3960 Howard Hughes Parkway      
Entity Address, Address Line Two Suite 500      
Entity Address, City or Town Las Vegas      
Entity Address, State or Province NV      
Entity Address, Postal Zip Code 89169      
City Area Code 917      
Local Phone Number 595-2850      
Title of 12(b) Security Common Stock, Par Value $0.0001 Per Share      
Trading Symbol PMCB      
Security Exchange Name NASDAQ      
Entity Well-known Seasoned Issuer No      
Entity Voluntary Filers No      
Entity Current Reporting Status Yes      
Entity Interactive Data Current Yes      
Entity Filer Category Non-accelerated Filer      
Entity Small Business true      
Entity Emerging Growth Company false      
Entity Shell Company false      
Entity Public Float       $ 12,527,115
Entity Common Stock, Shares Outstanding     6,795,779  
ICFR Auditor Attestation Flag false      
Document Financial Statement Error Correction [Flag] false      
Award Timing MNPI Disclosure [Text Block] We do not grant equity awards in anticipation of the release of material nonpublic information that is likely to result in changes to the price of our common stock, and do not time the public release of such information based on award grant dates. During the last completed fiscal year, we have not made awards to any named executive officer or director during the period beginning four business days before and ending one business day after the filing of a period report on Form 10-Q or Form 10-K or the filing or furnishing of a current report on Form 8-K, and we have not timed the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation.      
Award Timing MNPI Considered [Flag] false      
Auditor Firm ID 199 688    
Auditor Name CBIZ CPAs P.C. Marcum LLP    
Auditor Location Morristown, New Jersey Morristown, New Jersey